Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
复制标题
下一代测序（NGS）与下一代流式细胞术（NGF）在多发性骨髓瘤微小残留病（MRD）评估中的比较。
DOI：
10.1038/s41408-020-00377-0
复制
发表时间：
2020-10-30
影响因子：
12.8
通讯作者：
Garcia-Sanz R
中科院分区：
文献类型：
--
作者：
Medina A;Puig N;Flores-Montero J;Jimenez C;Sarasquete ME;Garcia-Alvarez M;Prieto-Conde I;Chillon C;Alcoceba M;Gutierrez NC;Oriol A;Rosinol L;Bladè J;Gironella M;Hernandez MT;Gonzalez-Calle V;Cedena MT;Paiva B;San-Miguel JF;Lahuerta JJ;Mateos MV;Martinez-Lopez J;Orfao A;Gonzalez M;Garcia-Sanz R
检测持续性微小残留病（MRD）可以识别复发和死亡风险增加的患者。在这项研究中，我们使用商业下一代测序（NGS）策略（LymphoTrack®）评估了106例骨髓瘤患者移植后3个月的MRD，并将结果与下一代flow （NGF, EuroFlow）进行了比较。不同骨髓抽取的使用和NGS浓缩样品的需要对MRD评估的适用性有偏见，而对NGF有利。尽管如此，NGS与NGF的相关性很高（R2 = 0.905）。未检测到的患者与阳性患者相比，NGS和NGF的3年无进展生存（PFS）率更长（NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%；两组比较p < 0.001），这导致了3年总生存（OS）优势（NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%，两组比较p < 0.01）。在Cox回归模型中，NGS和NGF阴性的结果相似，但在PFS （HR: 0.20, 95% CI: 0.09-0.45, p < 0.001）和OS （HR: 0.21, 95% CI: 0.06-0.75, p = 0.02）中倾向于后者。所有这些结果都加强了不同策略的MRD检测在患者预后中的作用，并强调了MRD作为多发性骨髓瘤治疗终点的应用。
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R2 = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
登录
查看更多内容
影响因子：
158.5
作者：
Mateos, M. -V.;Dimopoulos, M. A.;San-Miguel, J.
通讯作者：
San-Miguel, J.
DOI：
10.1038/nrclinonc.2014.239
发表时间：
2015-05
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Mailankody S;Korde N;Lesokhin AM;Lendvai N;Hassoun H;Stetler-Stevenson M;Landgren O
通讯作者：
Landgren O
影响因子：
11.4
作者：
Durie, B. G. M.;Harousseau, J-L;Rajkumar, S. V.
通讯作者：
Rajkumar, S. V.
影响因子：
20.3
作者：
Perrot, Aurore;Lauwers-Cances, Valerie;Munshi, Nikhil
通讯作者：
Munshi, Nikhil
影响因子：
10.1
作者：
Rawstron, Andy C.;Orfao, Alberto;Johnsen, Hans E.
通讯作者：
Johnsen, Hans E.